06/11/2025 | Press release | Distributed by Public on 06/12/2025 05:33
- -
On page 13 of the morning edition of the Nikkei Shimbun (dated June 6th), an article was published about the "AI program medical device for conversational cognitive function testing" jointly developed by Shionogi and FRONTEO, and introduced it as "Clinical trials begin for dementia diagnosis support AI." The device uses the company's proprietary specialized AI "KIBIT" to analyze free conversation and screen for cognitive decline, contributing to early detection and early treatment.
[Reference]
■FRONTEO's AI medical equipment https://lifescience.fronteo.com/products/dementia/
■Development of conversational AI-programmed medical equipment for cognitive function testing
-FRONTEO and Shionogi & Co. enter into strategic business alliance agreement regarding AI program business to support diagnosis of dementia and depression
-FRONTEO, Shionogi, and Suzuken Collaborate to Implement Conversational Dementia Diagnosis Support AI Program in Society
-The Ministry of Health, Labour and Welfare has designated the AI programmed medical device for conversational cognitive function testing (neuropsychological testing) (SDS-881) as a priority review item for programmed medical devices.
-FRONTEO and Shionogi have submitted a clinical trial notification for the "AI Programmed Medical Device for Conversational Cognitive Function Testing (SDS-881)" jointly developed by the two companies.
-FRONTEO and Shionogi Pharmaceuticals begin clinical trials of "AI-programmed medical device for conversational cognitive function testing (SDS-881)"